Back HBV Treatment Approved HBV Drugs

Approved HBV Drugs

AASLD 2011: Long-term Tenofovir for HIV/HBV Coinfection

Tenofovir showed long-term antiviral activity against hepatitis B virus (HBV) lasting 5 to 8 years, with minimal evidence of kidney toxicity, and HBsAg levels declined steadily over time, according to 2 posters presented this week at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) in San Francisco.

Read more:

Entecavir (Baraclude) Less Effective for Patients with Multidrug-Resistant Hepatitis B

The nucleoside analog antiviral drug entecavir (Baraclude) was minimally effective against hepatitis B virus (HBV) that had already developed resistance to lamivudine (Epivir-HBV) and adefovir (Hepsera), researchers reported in the October 2011 Journal of Viral Hepatitis. Patient who achieved good early response, however, can do well if they stay on entecavir.alt

Read more:

Early HBeAg Decrease Predicts Response to Entecavir (Baraclude) for Hepatitis B

Decreases in hepatitis B "e" antigen (HBeAg) during the first 6 months of treatment with entecavir (Baraclude) are a better indicator than hepatitis B virus (HBV) DNA levels of which patients will go on to achieve HBeAg seroconversion, according to a recent Chinese study.alt

Read more:

Long-Term Efficacy of Entecavir for People with Hepatitis B

Long-term entecavir (Baraclude) monotherapy leads to a virological response in a large majority of nucleoside/nucleotide analog-naive patients, even those who still have detectable HBV DNA at 48 weeks.alt

Read more:

Entecavir vs Adefovir in Hepatitis B Patients with Liver Decompensation

In a head-to-head comparison, entecavir (Baraclude) demonstrated superior virological efficacy compared to adefovir (Hepsera) in hepatitis B patients with decompensated liver disease.alt

Read more: